PPT-Anticoagulation in Atrial

Fibrillation Michelle Tsukamoto DSR 2 May 9 2018 PGY 2 1 Objectives Discuss which patients with atrial fibrillation should be anticoagulated for CVA prevention Learn about different oral anticoagulation options . The LAA is a normal part of the heart anatomy and causes no problems in the general population However this pouch is a major source of blood clots in patients with atrial fibrillation Atrial fibrillation AF is the biggest risk factor for blood clots Journal Club . October 21,2015. Kathleen McNamara, . PharmD. Stroke Risk Calculation. Which tool do you most typically use to evaluate stroke . risk for patients with a fib? . CHADS2 score. CHADS2-VASc. . . Feb 08/2014. Hanadi. . Alhozali,MBBS,ABIM,FRCPC. Assistant professor consultant internal medicine and Nephrology KAUH/Jeddah. Glomerular- based disease and Renal disease in pregnancy. Objectives. Rhea C. Pimentel, MD. Associate Professor of Medicine. Fellowship Program Director, Clinical Cardiac Electrophysiology Program. Disclosures. Speakers Bureau: Medtronic. Speakers Bureau: St. Jude Medical. A . CASE SERIES AND REVIEW OF THE LITERATURE . 1. Lily . K. . Fatula. , BS; . 1,2. William . D. Bolton, MD; . 1,2. Barry . R. Davis, MD; . 1,2. James . E. Stephenson, MD; . 1,2. Sharon . Ben-Or, MD. . Mary N. Healy, MS, ARNP-BC. Heart & Vascular Center of Sarasota. OBJECTIVES. Define the difference between paroxysmal and persistent Atrial Fibrillation. State the CVA risk per year of a 68 . yr. C. atheter . Ab. lation Versus . An. tiarrhythmic Drug Therapy for . A. trial Fibrillation (CABANA) Trial . Jeanne E. Poole MD, George Johnson BSEE, Kristi H. Monahan RN, Hoss Rostami BSMSE, . Adam Silverstein MS, Hussein Al-Khalidi PhD, Mauri Wilson RN, Yves Rosenberg MD, MPH, . A . CASE SERIES AND REVIEW OF THE LITERATURE . 1. Lily . K. . Fatula. , BS; . 1,2. William . D. Bolton, MD; . 1,2. Barry . R. Davis, MD; . 1,2. James . E. Stephenson, MD; . 1,2. Sharon . Ben-Or, MD. . Overview . Definition and epidemiology. Symptoms. Tests/Evaluations. Complications. Treatment. Effects on exercise. Medications effect on exercise. Effects of training. Exercise prescription. Definition. <1% of individuals aged 60 to 65 years . 8% to 10% of individuals aged >80 years . Men more than women . White persons more than black persons. Presence and severity of underlying heart disease increases risk . . John Windle MD October 18, 2013. Professor and Chief of Cardiology. University of Nebraska Medical Center. “Ha . ha. . ha. , Biff. Guess what? After we go to the drugstore and the post office, . R. ivaroxaban . I. n atrial . F. ibrillation patients . T. reated with left atrial appendage closure. ADRIFT . investigators. DOI public at www.action-coeur.org. Healing: 30 . days. to 3 . months. Kar et al. JACC Intv 2014;7:801-9. Geoffrey Barnes, MD, MSc. University of Michigan. @. GBarnesMD. May 14, 2020. Disclosures. Grants: Pfizer/Bristol-Myers Squibb, Blue Cross Blue Shield of Michigan, NHLBI, AHRQ. Consulting: Pfizer/Bristol-Myers Squibb, Janssen, Portola, AMAG Pharmaceuticals. Wessex. A report for Wessex AHSN ‘Atrial Fibrillation: Detect, Perfect, Protect’ . Programme. Dr . Anastasios. Argyropoulos. Centre for Implementation Science. A.Argyropoulos@soton.ac.uk . Wessex.